Single-Cell Analysis of Inflammatory Lung-Related Pathologies

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".

Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 432

Special Issue Editors

Special Issue Information

Dear Colleagues,

Chronic inflammation of the airway tract can emerge under different conditions, leading to life-threatening situations. (i) Tobacco smoking has been described as responsible for 87% of all lung-cancer-related deaths in the USA. Lung cancer is a heterogeneous disease classified by histology into small-cell lung carcinomas (22%) and non-small-cell carcinomas: adenocarcinomas (40%), squamous-cell carcinomas (30%), and large-cell carcinomas (8%). All types are influenced by smoking-related inflammation to different extents. Both cancer cells and the components of the tumor stroma of the lung are of interest. (ii) Smoking, dust, and gases generate inflammation in the airway tract via chronic inflammatory responses to irritants, frequently leading to chronic obstructive pulmonary disease (COPD). COPD and pulmonary fibrosis are the result of ongoing inflammatory processes in the lung, rendering the patient unable to breath. (iii) Irrespective of smoking habits, COVID-19, through the overwhelming immune reaction, fuels lung inflammation that is frequently fatal. We call authors to publish their latest results related to diseases such as lung cancer, COPD, and lung pathologies caused by COVID-19, with a special focus on studies of inflammation using single-cell-resolution technologies. State-of-the-art technologies such as single-cell mass cytometry, single-cell RNAseq, and laser microdissection may reveal unprecedented features of cellular sub-types linking different phenotypes with biological significance. Review articles with clear focuses will also be considered for peer review.

Dr. László G. Puskás
Dr. Gábor J. Szebeni
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lung cancer
  • COPD
  • COVID-19
  • single-cell proteomics
  • single-cell genomics

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop